Write your message
Volume 5, Issue 1 (Winter 2020)                   J Obstet Gynecol Cancer Res 2020, 5(1): 11-18 | Back to browse issues page


XML Print


Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:

Fouladi B, Rezaei Keikhaie K, Ghaemi M, Shirazi M, Ahmadian M, Rajabpoor Nikoo N, et al . Phenotypic Evaluation of Strains of Candida albicans and Non-albicans Candida Species in Patients with Vulvovaginal Candidiasis Visiting Amir-al-Momenin Hospital in Zabol, Iran in 2019. J Obstet Gynecol Cancer Res. 2020; 5 (1) :11-18
URL: http://jogcr.com/article-1-259-en.html
1- Department of Parasitology and Mycology, School of Medicine, Zabol University of Medical Sciences, Zabol, Iran
2- Department of Obstetrics and Gynecology, School of Medicine, Zabol University of Medical Sciences, Zabol, Iran , khrezaei@gmail.com
3- Maternal, Fetal and Neonatal Research Center, Tehran University of Medical Sciences, Tehran, Iran
4- Yas Hospital, Tehran University of Medical Sciences
5- Shohada Hospital, Qom University of Medical Sciences, Qom, Iran
Abstract:   (452 Views)

Background & Objective: Vulvovaginal candidiasis (VVC) is a common vaginal yeast infection in women. The present study aimed to determine the phenotype of Candida albicans and non-albicans Candida species in VVC cases.

Materials & Methods: This was a cross-sectional study on 65 patients suspected of VVC through a visit by a gynecologist. They were cultured on CHROMagar and Sabouraud dextrose agar (SDA). If morphology of the colonies could be detected through microscopic inspection, physiological tests were used to identify individual yeast species.

Results: Out 65 colonies, 53.8% had negative cultures. The frequency of positive cultures for Candida were also calculated (C. albicans = 38.5%, C. glabrata = 6.15%, and C. krusei = 1.53%). Most of culture-negative cases had no history of antibiotic therapy (94.3%) while most of culture-positive cases had a history of fluconazole therapy (56% in C. albicans isolates and 40% in non-C. albicans isolates). Relapse rate was calculated as 29.2%. Of studied patients, 80% had no underlying disease, 15.4% had a history of diabetes, and 4.6% had a history of corticosteroid therapy. Less than half negative-culture cases had an undergraduate degree (45.7%).

Conclusion: The incidence of VVC depends on various factors including occupation, underlying disease and history of antibiotic therapy. The most common cause of VVC is C. glabrata, secondary to C. albicans. Relapse infection rates can be reduced by increasing knowledge on clinical data, underlying diseases, mechanism of the organism, cause of infection, and effective treatment.

Full-Text [PDF 849 kb]   (166 Downloads) |   |   Full-Text (HTML)  (120 Views)  
Systematic Review: Original Research | Subject: Pathology
Received: 2020/04/14 | Accepted: 2020/07/20 | Published: 2020/07/20

References
1. Geiger A, Foxman B, Sobel J. Chronic vulvovaginal candidiasis: characteristics of women with Candida albicans, C glabrata and no candida. Sexual Transmit Infect. 1995;71(5):304-7. [DOI:10.1136/sti.71.5.304] [PMID] [PMCID]
2. Anaissie EJ, McGinnis MR, Pfaller MA. Clinical Mycology E-Book: Elsevier Health Sciences; 2009.
3. Sobel JD. Epidemiology and pathogenesis of recurrent vulvovaginal candidiasis. Am J Obstet Gynecol. 1985;152(7):924-35. [DOI:10.1016/S0002-9378(85)80003-X]
4. Sobel JD. Vulvovaginitis: when Candida becomes a problem. Dermatol Clin. 1998;16(4):763-8. [DOI:10.1016/S0733-8635(05)70043-7]
5. SJ H. Prevalence of candida and non-candida yeasts isolated from patients with yeast fungal infections in Tehran labs. Tehran Uni Med J TUMS Pub. 2011;69(1):55-62.
6. Consolaro ML, Albertoni TA, Yoshida CS, Mazucheli J, Peralta RM, Svidzinski TE. Correlation of Candida species and symptoms among patients with vulvovaginal candidiasis in Maringá, Paraná, Brazil. Rev Iberoam Micol. 2004;21(4):202-5.
7. ESMAEILZADEH S, MAHDAVI OS, Rahmani Z. Frequency and etiology of vulvovaginal candidiasis in women referred to a gynecological center in Babol, Iran. 2009.
8. Grigoriou O, Baka S, Makrakis E, Hassiakos D, Kapparos G, Kouskouni E. Prevalence of clinical vaginal candidiasis in a university hospital and possible risk factors. Euro J Obstet Gynecol Reproduct Biol. 2006;126(1):121-5. [DOI:10.1016/j.ejogrb.2005.09.015] [PMID]
9. Goswami D, Goswami R, Banerjee U, Dadhwal V, Miglani S, Lattif AA, et al. Pattern of Candida species isolated from patients with diabetes mellitus and vulvovaginal candidiasis and their response to single dose oral fluconazole therapy. J Infect. 2006;52(2):111-7. [DOI:10.1016/j.jinf.2005.03.005] [PMID]
10. Sehgal V, Bajwa SJS, Sehgal R, Consalvo JA. Management of diabetes mellitus in the elderly with canagliflozin: a newer hypoglycemic drug on the horizon. J Pharmacol Pharmacotherap. 2014;5(4):227. [DOI:10.4103/0976-500X.142428] [PMID] [PMCID]
11. Mandell G, Dolin R, Bennett J. Mandell, Douglas, and Bennett's principles and practice of infectious diseases: Elsevier; 2009.
12. Fidel Jr PL. History and new insights into host defense against vaginal candidiasis. Trends in microbiology. 2004;12(5):220-7. [DOI:10.1016/j.tim.2004.03.006] [PMID]
13. Kariman N, Shafai Z, Afrakhte M, Valai N, Ahmadi M. Comparative study of traputic effects of fluconazole and clotrimazole on candida vaginitis. J Behbood. 2002;6(13):9-16.
14. Martinez R, Franceschini SA, Patta MC, Quintana SM, Candido RC, Ferreira JC, et al. Improved treatment of vulvovaginal candidiasis with fluconazole plus probiotic Lactobacillus rhamnosus GR‐1 and Lactobacillus reuteri RC-14. Lettr Appl Microbiol. 2009;48(3):269-74. [DOI:10.1111/j.1472-765X.2008.02477.x] [PMID]
15. Habibian R, Jafarzadeh L, Shahriari K. Investigating the relationship between recurrent vulvovaginal candidiasis with predisposing factors and symptoms of disease. J Shahrekord Uni Med Sci. 2013;15.
16. Aghamirian M, Jahani Hashemi H. Agents associated with candida vulvovaginitis in women referred to health centers in Qazvin. J Qazvin Uni Med Sci. 2007;11(3):35-9.
17. Nazeri M, Mesdaghinia E, Moraveji SAR, Atabakhshiyan R, Soleymani F. Prevalence of vulvovaginal candidiasis and frequency of Candida species in women referred to gynecology obstetrics clinic at Kashan-Iran since 2008 to 2010. J Mazand Univ Med Sci. 2012;22:262-9.
18. Akbarzadeh M, Bonyadpoure B, Pacshir K, Mohagheghzadeh A. Causes and clinical symptoms of vaginal candidiasis in patients referring to selective clinics of Shiraz University of Medical Sciences (2009). J Arak Uni Med Sci. 2010 Sep 10;13(3):12-20.
19. Panahi F, Kordbacheh P, Rezaie S, Zeini F, Zeraati H, Safara M. Determination of candida species in acute and recurrent candida vulvovaginitis. 2009.
20. Nyirjesy P, Seeney SM, Grody MHT, Jordan CA, Buckley HR. Chronic fungal vaginitis: the value of cultures. Am J Obstet Gynecol. 1995;173(3):820-3. [DOI:10.1016/0002-9378(95)90347-X]
21. Paulitsch A, Weger W, Ginter‐Hanselmayer G, Marth E, Buzina W. A 5‐year (2000-2004) epidemiological survey of Candida and non‐Candida yeast species causing vulvovaginal candidiasis in Graz, Austria. Mycoses. 2006;49(6):471-5. [DOI:10.1111/j.1439-0507.2006.01284.x] [PMID]
22. Jawetz E, Melnick JL, Adelberg EA. Review of medical microbiology.1984.
23. Murray PR, Rosenthal KS, Pfaller MA. Medical microbiology: Elsevier Health Sciences; 2015.
24. SH M, MR S, SJ H. Identification of Pathogenic Candida Species: PCR-Fragment Size Polymorphism (PCR-FSP) Method. Tehran Uni Med J TUMS Pub. 2008;66(9):639-45.
25. Tietz H, Küssner A, Thanos M, De Andrade MP, Presber W, Schönian G. Phenotypic and genotypic characterization of unusual vaginal isolates of Candida albicans from Africa. J Clin Microbiol. 1995;33(9):2462-5. [DOI:10.1128/JCM.33.9.2462-2465.1995] [PMID] [PMCID]
26. Mendling W. Vulvovaginal candidosis. Urogenital Infections. 1987:912. [DOI:10.1007/978-3-642-83312-0]
27. Baykushev R, Ouzounova-Raykova V, Stoykova V, Mitov I. Reliable microbiological diagnosis of vulvovaginal candidiasis. Akusherstvo i ginekologiia. 2014;53(4):17-20.
28. Monod M, Togni G, Hube B, Sanglard D. Multiplicity of genes encoding secreted aspartic proteinases in Candida species. Molecul Microbiol. 1994;13(2):357-68. [DOI:10.1111/j.1365-2958.1994.tb00429.x] [PMID]
29. Hosseini SS, Ghaemi E, Niknejad F, Joshaghani H, Rabiee M, Azadi F, et al. Investigation of the relationship between different Candida species and some risk factors affecting the incidence of Vulvovaginal Candidiasis. The Iranian Journal of Obstetrics, Gynecol Infert. 2019;22(7):13-22.
30. Ghahri M. Systemic fungal infections: Candidiasis-aspergillosis. Iran J Pathol. 2009;35:24-6.
31. Nozhat F, Zarei M. Association between clinical symptoms and laboratory findings in the diagnosis of Candida vaginitis. KAUMS J (FEYZ). 2016;20(2):173-9.
32. Fatima N, Zareii M. Evaluation of Clinical Symptoms and Laboratory Results in Diagnosis of Candida Vaginitis. 2016.
33. Shokohi T, Soteh MH, Pouri ZS, Hedayati M, Mayahi S. Identification of Candida species using PCR-RFLP in cancer patients in Iran. Ind J Med Microbiol. 2010;28(2):147. [DOI:10.4103/0255-0857.62493] [PMID]
34. Falahati M, Sharifinia S, Foroumadi A, Bolouri F, Akhlagh L, Yazdan Parast A, et al. Drug resistance pattern in Candida species isolated from vaginitis. Razi J Med Sci. 2009;16:0-.
35. Mahmoudabadi AZ, Najafyan M, Alidadi M. Clinical study of Candida vaginitis in Ahvaz, Iran and susceptibility of agents to topical antifungal. Pak J Med Sci. 2010 Jul 1;26(3):607-10.
36. Kennedy H, Shankland G, Bagg J, Chalmers E, Gibson B, Williams C. Fluconazole and itraconazole susceptibilities of Candida spp. isolated from oropharyngeal specimens and blood cultures of paediatric haematology/oncology patients. Mycoses. 2006;49(6):457-62. [DOI:10.1111/j.1439-0507.2006.01272.x] [PMID]
37. Moreira D, Paula C. Vulvovaginal candidiasis. Int J Gynecol Obstet. 2006;92(3):266-7. [DOI:10.1016/j.ijgo.2005.12.007] [PMID]
38. Pakshir K, Yazdani M, Kimiaghalam R. Etiology of vaginal candidiasis in Shiraz, Southern Iran. Res J Microbiol. 2007;2:696-700. [DOI:10.3923/jm.2007.696.700]
39. Hosseini SS, Ghaemi E, Noroozi A, Niknejad F. Zinc Oxide nanoparticles inhibition of initial adhesion and ALS1 and ALS3 gene expression in Candida albicans strains from urinary tract infections. Mycopathologia. 2019;184(2):261-71. [DOI:10.1007/s11046-019-00327-w] [PMID]
40. Zeng X, Zhang Y, Zhang T, Xue Y, Xu H, An R. Risk factors of vulvovaginal candidiasis among women of reproductive age in Xi'an: a cross-sectional study. BioMed Res Int. 2018;2018. [DOI:10.1155/2018/9703754] [PMID] [PMCID]
41. Yokoyama H, Nagao A, Watanabe S, Honjo J. Incidence and risk of vaginal candidiasis associated with sodium-glucose cotransporter 2 inhibitors in real‐world practice for women with type 2 diabetes. J Diab Invest. 2019;10(2):439-45. [DOI:10.1111/jdi.12912] [PMID] [PMCID]
42. Bitew A, Abebaw Y. Vulvovaginal candidiasis: species distribution of Candida and their antifungal susceptibility pattern. BMC Women's Health. 2018;18(1):94. [DOI:10.1186/s12905-018-0607-z] [PMID] [PMCID]

Add your comments about this article : Your username or Email:
CAPTCHA

Send email to the article author


© 2020 All Rights Reserved | Journal of Obstetrics, Gynecology and Cancer Research (JOGCR)

Designed & Developed by : Yektaweb | Piblisher: Farname Inc.